Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP2 | Q9HC62 | 7/20 | 1.00 |
| ▸ | SENP1 | Q9P0U3 | 7/20 | 1.00 |
| ▸ | SENP3 | Q9H4L4 | 5/20 | 1.00 |
| ▸ | SUMO2 | P61956 | 4/20 | 1.00 |
| ▸ | SUMO1 | P63165 | 4/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592202 | 1.00 | SENP2 (1.00) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL2592201 | 1.00 | SENP2 (1.00) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL15393681 | 0.95 | SENP3 (0.90) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL12177914 | 0.94 | SENP3 (0.88) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL12177942 | 0.92 | SENP3 (0.85) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL12177911 | 0.92 | SENP3 (0.85) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL2594010 | 0.91 | SENP3 (0.83) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL2583416 | 0.91 | SENP3 (0.83) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL2594013 | 0.91 | SENP3 (0.83) | SENP2SENP1SENP3SUMO2SUMO1 | |
| SCHEMBL2583414 | 0.91 | SENP3 (0.83) | SENP2SENP1SENP3SUMO2SUMO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | CureVac SE (DE) | 2025-03-13 | — | — | US | claimed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| US-12289600-B2 | Establishing multiple security associations in a connection operation | ARISTA NETWORKS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| CN-115395067-B | Acid-base blend membrane for proton exchange membrane fuel cell and preparation method thereof | 中北大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-119655359-A | Method for enhancing gel property of isolated soy protein by using rice protein amyloid fiber | 黑龙江八一农垦大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20240382651-A1 | BUPIVACAINE-COLLAGEN DRUG DELIVERY IMPLANT AND METHODS OF MAKING AND USING THEREOF | INNOCOLL PHARM LTD (IE) | 2024-11-21 | — | — | US | disclosed |
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118251214-A | Bupivacaine-collagen drug delivery implants and methods of making and using the same | 因诺科尔制药有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115005372-B | Preparation method of high-protein quinoa gluten-free noodles | 江南大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-219145399-U | Intelligent terminal system based on accurate time service of 5G | 利尔达科技集团股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-115395067-A | Acid-base blend membrane for proton exchange membrane fuel cell and preparation method thereof | 中北大学 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022219179-A1 | DRUG-RELEASE IMPLANT FOR SOFT TISSUE SURGERY | INNOCOLL PHARMACEUTICALS LIMITED (IE) | 2022-10-20 | — | — | WO | disclosed |
| CN-115005372-A | Preparation method of high-protein quinoa gluten-free noodles | 江南大学 | 2022-09-06 | — | — | CN | disclosed |
| US-20220279350-A1 | ESTABLISHING MULTIPLE SECURITY ASSOCIATIONS IN A CONNECTION OPERATION | ARISTA NETWORKS, INC. | 2022-09-01 | — | — | US | disclosed |
| CN-111095091-B | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element | 日产化学株式会社 | 2022-08-26 | — | — | CN | disclosed |
| US-20220215268-A1 | SAMPLE ANALYSIS METHOD AND DEVICE BASED ON KERNEL MODULE IN GENOMIC MODULE NETWORK | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2022-07-07 | — | — | US | disclosed |
| CN-110945418-B | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element | 日产化学株式会社 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SENP2 2152/4885SENP1 1896/4885SENP3 1371/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SENP2 2152/4885SENP1 1896/4885SENP3 1371/4885 |
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | NSUN3, SARNP, TRDMT1 | SENP2 1300/4885SENP1 1194/4885SENP3 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.